2 results
Approved WMOCompleted
Primary ObjectiveThe primary objective of this study is to determine whether nSTRIDE APS is superior to HA in mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) LK 3.1 pain score (change from baseline to 12 months post-…
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.